BioSpace News Archive

Seegene Inc., a molecular diagnostics company reported its financial results for the first quarter of 2021, with reports showing robust earnings.

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today positive topline results from its U.S. Phase II IXPLORE study with vilobelimab in patients with anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis, or AAV.

Vivos Therapeutics, Inc. (Nasdaq: VVOS) (“Vivos”), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (OSA), today announced the closing of its underwritten follow-on public offering of 4,600,000 shares of its common stock

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.

Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company.

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today reported financial results for the three months ended March 31, 2021.

Exagen Inc., a leading provider of autoimmune testing solutions, reported financial results for the quarter ended March 31, 2021.

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today reported financial results and business progress for the first quarter ended March 31, 2021.

Annual Meeting to be adjourned solely with respect to Proposal 3

Inari Medical, Inc. a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its first quarter ended March 31, 2021.